Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1046-1054

  Azoulay Dupuis, E ^a   Bedos J P ^a   Mohler, J ^a   Moine, P ^a   Cherbuliez, C ^b   Peytavin, G ^a   Fantin, B ^a   Kohler T ^b  

^a INSERM   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ETHIDIUM BROMIDE; GEMIFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG TISSUE LEVEL; IN VITRO STUDY; LUNG; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTATION; NONHUMAN; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

EID: 14744268779     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1046-1054.2005     Document Type: Article

References (40)

1. Allen, A., E. Bygate, S. Oliver, M. Johnson, C. Ward, A. J. Cheon, Y. S. Choo, and I. C. Kim. 2000. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 44:1604-1608.
2. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
3. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
4. Appelbaum, P. C. 1996. Emergence of resistance to antimicrobial agents in gram-positive bacteria. Pneumococci. Drugs 51(Suppl. 1):1-5.
5. Azoulay-Dupuis, E., E. Vallée, B. Veber, J. P. Bédos, J. Bauchet, and J. J. Pocidalo. 1992. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob. Agents Chemother. 36:2698-2703.
6. Azoulay-Dupuis, E., J. P. Bédos, J. Mohler, G. Peytavin, R. Isturiz, P. Moine, V. Rieux, C. Cherbuliez, J. C. Péchère, B. Fantin, and T. Köhler. 2004. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob. Agents Chemother. 48:765-773.
7. Bartlett, J. G., R. F. Breiman, L. A. Mandell, T. M. File, D. Musher, and M. Fine. 2000. Community acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 31:347-382.
8. Bédos, J. P., V. Rieux, J. Bauchet, M. Muffat-Joly, C. Carbon, and E. Azoulay-Dupuis. 1998. Efficacy of trovafloxacin against penicillin- susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 42:862-867.
9. Boos, M., S. Mayer, A. Fisher, K. Kôhrer, S. Scheuring, S. Heisig, J. Verhoef, A. D. C. Fluit, and F. J. Schmitz. 2001. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob. Agents Chemother. 45:938-942.
10. Boswell, F. J., J. M. Andrews, G. Jevons, and R. Wise. 2002. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J. Antimicrob. Chemother. 50:495-502.
11. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
12. Broskey, J., K. Coleman, M. N. Gwynn, L. McLoskey, C. Traini, L. Voelker, and R. Warren. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 45:95-99.
13. Chen, D. K., A. McGeer, J. C. de Azavedo, D. E. Low, et al. 1999. Decreased susceptibility of Streptococcus pneumoniae in Canada. N. Engl. J. Med. 341:233-239.
14. Davies, T. A., L. M. Kelly, G. A. Pankuck, K. M. Credito, M. R. Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob. Agents Chemother. 44:304-310.
15. Dubois, J., and C. St-Pierre. 2000. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp. J. Antimicrob. Chemother. 45(Suppl. S1):41-46.
16. Duffy, L. B., D. Crabb, K. Searcey, and M. C. Kempf. 2000. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycloplasma spp. J. Antimicrob. Chemother. 45(Suppl. S1):29-33.
17. European Commission. 1986. Directive for the protection of vertebrate animals used for experimental and other scientific purposes (86/609/EEC). Off. J. C. Eur. Comm. L. 358:1-29.
18. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
19. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
20. Gillespie, S. H., L. L. Voelker, and A. Dickens. 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb. Drug Resist. 8:79-84.
21. Hansen, G. T., K. Metzler, K. Drlica, and J. M. Blondeau. 2003. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:440-441.
22. Heaton, V. J., C. E. Goldsmith, J. E. Ambler, and L. M. Fisher. 1999. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Antimicrob. Agents Chemother. 43:2998-3000.
23. Heaton, V. J., J. E. Ambler, and L. M. Fisher. 2000. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complex in vitro. Antimicrob. Agents Chemother. 44:3112-3117.
24. Janoir, C., V. Zeller, M. Kitzis, N. J. Moreau, and L. Gutman. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
25. Jorgensen, J. H., L. M. Weigel, J. M. Swenson, C. G. Whitney, M. J. Ferraro, and M. C. Tenover. 2000. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2962-2968.
26. King, A., J. May, G. French, and I. Phillips. 2000. Comparative in vitro activity of gemifloxacin. J. Antimicrob. Chemother. 45(Suppl. S1):1-12.
27. Lieberman, D., F. Schlaeffer, H. Boldur, D. Lieberman, S. Horowitz, M. Leinonen, O. Horowitz, E. Manor, and A. Porath. 1996. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51:179-184.
28. Moine, P., J. B. Vercken, S. Chevret, C. Chastang, P. Gajdos, and the French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. 1994. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. Chest 105:1487-1495.
29. Morrissey, I., and J. T. George. 2000. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. 45(Suppl. S1):107-110.
30. Munoz, R., and A. G. De La Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
31. Nagai, K., T. A. Davies, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2001. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J. Antimicrob. Chemother. 48:365-374.
32. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial disk susceptibility tests; approved standard, 7th ed., M2-A7. vol. 20, no. 1. National Committee for Clinical Laboratory Standards, Wayne, Pa.
33. Pallarés, R., J. Linarés, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
34. Pan, X. S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
35. Piddock, L. J., M. Johnson, and S. L. Hill. 1998. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob. Agents Chemother. 42:2956-2960.
36. Reinert, R. R., A. Al-Lahham, R. Lütticken, M. Boos, and F. J. Schmitz. 2002. Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones J. Antimicrob. Chemother. 49:1015-1018.
37. Rittenhouse, S., L. McCloskey, J. Broskey, N. Niconovich, C. Jakielaszek, J. Poupard, and K. Coleman. 2000. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. J. Antimicrob. Chemother. 45(Suppl. S1):23-27.
38. Saravolatz, L. D., and L. Leggett. 2003. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of newer fluoroquinolones. Rev. Anti-Infect. Agents 37:1210-1215.
39. Wise, R., and J. M. Andrews. 1999. The in-vitro activity and tentative break-point of gemifloxacin, a new fluoroquinolone. J. Antimicrob. Chemother. 44:679-688.
40. Zeller, V., C. Janoir, M. Kitzis, L. Gutmann., and N. J. Moreau. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978.